Lung S. Yam
Fondateur chez Cyprium Therapeutics, Inc.
Profil
Lung S.
Yam is the founder and currently serves as the Chief Executive Officer & Director of Cyprium Therapeutics, Inc., a company founded in 2017.
In the past, Dr. Yam worked as an Associate Biotechnology Analyst at Rodman & Renshaw LLC (Old) from 2008 to 2009 and as a Principal at Lenox Hill Hospital from 2005 to 2008.
Dr. Yam also held the position of Senior Analyst at Opus Point Partners Management LLC.
Postes actifs de Lung S. Yam
| Sociétés | Poste | Début |
|---|---|---|
Cyprium Therapeutics, Inc.
 Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Fondateur | 01/01/2017 |
Anciens postes connus de Lung S. Yam
| Sociétés | Poste | Fin |
|---|---|---|
Rodman & Renshaw LLC (Old)
 Rodman & Renshaw LLC (Old) Investment Banks/BrokersFinance Founded in 2003 by Cliff Rodman and Charles Renshaw, Rodman & Renshaw LLC is a full-service investment bank and broker/dealer located in New York City with an additional office in Boston. The firm is a subsidiary of Rodman & Renshaw Capital Group (NasdaqGM: RODM). The firm provides corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. They also provide research and sales and trading services to institutional investors. Rodman & Renshaw is a leader in the PIPE and RD (registered direct offering) transaction markets. The firm's research focuses on Asia, clean technology, community & regional banks, energy, industrial and commercial services, life science/healthcare and metals and mining. Rodman & Renshaw is a member of the NASD and the SIPC. | Analyst-Equity | 01/03/2009 |
Lenox Hill Hospital
 Lenox Hill Hospital Hospital/Nursing ManagementHealth Services Lenox Hill Hospital provides health care services. It services include cardiac care, high-risk obstetrics, pediatrics, ophthalmology, orthopedics, and sports medicine. The firm's facility serves as a teaching affiliate for NYU Medical Center and also owns Manhattan Eye, Ear & Throat Hospital, a provider of specialty care for vision, hearing, speech and even swallowing disorders. The company was founded in 1857 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/07/2008 |
Opus Point Partners Management LLC
 Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Analyst-Equity | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Rodman & Renshaw LLC (Old)
Rodman & Renshaw LLC (Old) Investment Banks/BrokersFinance Founded in 2003 by Cliff Rodman and Charles Renshaw, Rodman & Renshaw LLC is a full-service investment bank and broker/dealer located in New York City with an additional office in Boston. The firm is a subsidiary of Rodman & Renshaw Capital Group (NasdaqGM: RODM). The firm provides corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. They also provide research and sales and trading services to institutional investors. Rodman & Renshaw is a leader in the PIPE and RD (registered direct offering) transaction markets. The firm's research focuses on Asia, clean technology, community & regional banks, energy, industrial and commercial services, life science/healthcare and metals and mining. Rodman & Renshaw is a member of the NASD and the SIPC. | Finance |
Opus Point Partners Management LLC
Opus Point Partners Management LLC Investment ManagersFinance Opus Point Partners Management LLC (OPPM) is a hedge fund manager headquartered in New York City. The firm was founded by Lindsay Rosenwald and Michael Weiss in 2009. They are owned by Opus Point Partners LLC, which is a subsidiary of Weiss & Co. LLC. OPPM manages investments that are dedicated to healthcare and life science. | Finance |
Lenox Hill Hospital
Lenox Hill Hospital Hospital/Nursing ManagementHealth Services Lenox Hill Hospital provides health care services. It services include cardiac care, high-risk obstetrics, pediatrics, ophthalmology, orthopedics, and sports medicine. The firm's facility serves as a teaching affiliate for NYU Medical Center and also owns Manhattan Eye, Ear & Throat Hospital, a provider of specialty care for vision, hearing, speech and even swallowing disorders. The company was founded in 1857 and is headquartered in New York, NY. | Health Services |
Cyprium Therapeutics, Inc.
Cyprium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Fortress Biotech, Inc., Cyprium Therapeutics, Inc. is an American New York-based company focused on developing novel therapies for the treatment of Menkes disease and related copper metabolism disorders. The company was granted FDA breakthrough therapy, fast track, and rare pediatric disease designations, as well as FDA orphan drug designation for both Cutx-101 and AAV-ATP7A. The European Medicines Agency also granted orphan drug designation to Cyprium. In March 2017, Cyprium entered into a cooperative research and development agreement with the Eunice Kennedy Shriver National Institute of Child Health and Human Development to advance the clinical development of Cutx-101 for the treatment of Menkes disease. In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to Cutx-101 to Sentynl Therapeutics, Inc. Cyprium and NICHD also previously entered into a worldwide, exclusive license agreement to develop and commercialize AAV-ATP7A gene therapy, which is currently in pre-clinical development. The company was founded in 2017 by Michael Sean Weiss, Lindsay Allan Rosenwald, and Lung S. Yam, who has been the CEO since then. | Commercial Services |